Donald Berry
唐纳德·贝里
PhD
Professor Emeritus, Department of Biostatistics; Founding Member, Berry Consultants生物统计学系荣誉教授；Berry咨询创始人
👥Biography 个人简介
Donald Berry, PhD is a world-renowned biostatistician at MD Anderson and pioneer of Bayesian adaptive clinical trial design. He co-developed the I-SPY breast cancer trial platform, transforming how adaptive randomization and Bayesian methods are applied in oncology to accelerate drug development.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bayesian Adaptive Clinical Trial Design
Pioneered the application of Bayesian statistics to adaptive clinical trial design, enabling real-time learning and response-adaptive randomization that dramatically improves trial efficiency.
I-SPY Trial Platform
Co-developed the I-SPY (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis) platform, a flagship adaptive neoadjuvant breast cancer trial that tests multiple agents simultaneously.
Representative Works 代表性著作
Bayesian Clinical Trials
Nature Reviews Drug Discovery (2006)
Seminal review establishing the rationale and methodology for Bayesian approaches in clinical drug development, cited thousands of times.
Adaptive Randomization of Neratinib in Early Breast Cancer (I-SPY 2)
New England Journal of Medicine (2016)
Landmark I-SPY 2 publication demonstrating how adaptive randomization identifies effective therapies in biomarker-defined breast cancer subtypes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 唐纳德·贝里 的研究动态
Follow Donald Berry's research updates
留下邮箱，当我们发布与 Donald Berry（MD Anderson Cancer Center, University of Texas）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment